Skip to main content
SpringerLink
Log in

Effect of the Serotonin Antagonists Ritanserin and Ketanserin in Cushing's Disease

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Central serotonergic regulation couldhave a role in the course of pituitary-dependent Cushing's disease. We studied the effects of ritanserin and ketanserin, two related selective 5HT2 receptor antagonists, in 11 patients with Cushing's disease. Treatment lasted from 1 month to 1 year (up to 4 years in one patient). Daily doses were 10—15 mg for ritanserin, and 40—80 mg for ketanserin. Since the two drugs share the same mechanism of action and no qualitative or quantitative differences in response to their administration were observed, the results were pooled together. Patients were assessed by clinical and hormonal evaluation. Urinary cortisol and ACTH were considered the parameters of interest. Short-term response: after 1 month, there was a signi~cant decrease of urinary cortisol from 781 (160) to 331 (215) nmol/d (P > 0.02) while ACTH was 9.8 (1.5) pmol/L baseline and again 8.8 (2.2) pmol/L at 1 month (P × NS). For 9 patients, hormonal parameters were available after 1 week of treatment. In this case, also ACTH levels were signi~cantly decreased (from 9.6 (1.7) to 5.2 (1.3) pmol/L; P > 0.01) together with urinary cortisol (from 781 (194) to 372 (165) nmol/d; > 0.01). Long-term response: in 3 patients, hormonal parameters failed to respond to serotonin receptor antagonists, which were thus discontinued. An improvement was recorded in the remaining 8 patients, that was prolonged in 3, and transient in 5. In 3 of these latter patients, a marked increase of ACTH was observed before treatment discontinuation. Ketanserin was given to 2 patients with Nelson's sydrome, with only transient ACTH decrease in one, and no changes in ACTH response to CRH after 1 month treatment in both cases. An inhibitory effect of ritanserin and ketanserin on ACTH and cortisol production in Cushing's disease appeared to be limited both in terms of duration of response and number of patients with a satisfactory outcome. However, the results may provide a better understanding of serotonergic modulation in Cushing's disease and lead to therapeutic developments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Krieger DT, Amorosa L, Limick F. Cyproheptadine-induced remission of Cushing's disease. N Engl J Med 1975;293: 893–896.

    Google Scholar 

  2. Miller JW, Crapo L. The medical treatment of Cushing's syndrome. Endocrol Rev 1993;14:443–458.

    Google Scholar 

  3. Sonino N, Boscaro, M. Medical therapy for Cushing's disease. Endocrinol Metab Clin North Am 1999;28:211–222.

    Google Scholar 

  4. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA. International union pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157–203.

    Google Scholar 

  5. Grossman A. What is the cause of Cushing's disease? Clin Endocrinol 1992;36:451–452.

    Google Scholar 

  6. Biller MK. Pathogenesis of pituitary Cushing's syndrome. Endocrinol Metab Clin North Am 1994;23:547–553.

    Google Scholar 

  7. Leysen JE, Gommeren W, van Gompel P, Wynants J, Janssen PFM, Laduron PM. Receptor-binding properties in vitro and in vivo of ritanserin. Mol Pharmacol 1985;27:600–611.

    Google Scholar 

  8. Awouters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ. Pharmacological profile of ritanserin: a very specific central serotonin S2-antagonist. Drug Dev Res 1988;15:61–73.

    Google Scholar 

  9. Kristiansen K, Dahl SG. Molecular modeling of serotonin, ketanserin, ritanserin and their 5HT2C receptor interactions. Eur J Pharmacol 1996;306:195–210.

    Google Scholar 

  10. Stefanski R, Goldberg SR. Serotonin 5HT2 receptor antagonists. Potential in the treatment of psychiatric disorders. CNS Drugs 1997;7:308–409.

    Google Scholar 

  11. Bernini GP, Argenio GF, Vivaldi MS, Del Corso C, Birindelli R, Luisi M, Franchi F. Impaired growth hormone response to insulin-induced hypoglycemia in obese patients: restoration blocked by ritanserin after fenfluramine administration. Clin Endocrinol 1990;32:453–459.

    Google Scholar 

  12. Falaschi P, Rosa M, Rocco A, d'Urso R, Proietti A,Melis GB. Effect of ritanserin, specific 5HT2 antagonist, on PRL secretion in normal subjects and in different hyperprolactinaemic conditions. Clin Endocrinol 1991;34:449–453.

    Google Scholar 

  13. Facchinetti F, Martignoni E, Nappi G, Marini S, Petraglia F, Sandrini G, Genazzani AR. Ritanserin, a serotonin-S2 receptor antagonist, does not prevent 5-hydroxytryptophan-induced β-EP, β-LPH and cortisol secretion. Horm Res 1987; 27:42–46.

    Google Scholar 

  14. Tepavcevic P, Gibjevic Z, Aganovic I, Korsic M, Halimi S, Suchanek E, Jelic T, Kozic B, Plavsic V. Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans. J Endocrinol Invest 1995; 18:427–430.

    Google Scholar 

  15. Seibyl JP, Kristal JH, Price LH, Woods SW, D'Amico C, Heninger GR, Charney DS. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to metachlorophenylpiperazine in healthy human subjects. Psychiatry Res 1991;38:227–236.

    Google Scholar 

  16. Frishman WH, Huberfeld S, Okin S, Wang YH, Kumar A, Shareef B. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol 1995;35:541–572.

    Google Scholar 

  17. Cohen ML, Bloomquist WL, Snoddy HD, Fuller RW. Lack of a difference between ketanserin and ritanserin in central versus peripheral serotonin receptor antagonism. Life Sci 1989;45:1185–1189.

    Google Scholar 

  18. Van Nueten JM, Schuurkes JAJ, De Ridder WJE, Kuyps JJMD, Janssens WJ. Comparative pharmacological profile of ritanserin and ketanserin. Drug Dev Res 1986;8:187–195.

    Google Scholar 

  19. Marwood JF. Influence of alpha1-adrenoceptor antagonism of ketanserin on the nature of its 5HT2 receptor antagonism. Clin Exp Pharmacol Physiol 1994;21:955–961.

    Google Scholar 

  20. Prescott RWG, Kendall-Taylor P, Weightman DR, Watson MJ, Ratcliffe WA. The effects of ketanserin, a specific serotonin antagonist on the PRL, GH, ACTH and cortisol responses to hypoglycemia in normal subjects. Clin Endocrinol 1984;20:137–142.

    Google Scholar 

  21. Sonino N, Boscaro M, Fallo F, Fava GA. Potential therapeutic effects of ritanserin in Cushing's disease. JAMA 1992;267:1073.

    Google Scholar 

  22. Kaye TB, Crapo L. The Cushing's syndrome: an update on diagnostic tests. Ann Intern Med 1990;112:434–444.

    Google Scholar 

  23. Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 1996;81:2647–2642.

    Google Scholar 

  24. Boscaro M, Rampazzo A, Paoletta A, Roseano P, Pagotto U, Fallo F, Sonino N. Selective venous sampling in differential diagnosis of ACTH-dependent Cushing's syndrome. Neuroendocrinology 1992;55:264–268.

    Google Scholar 

  25. Pesarin F. On a nonparametric combination method for dependent permutation tests with applications. Psychother Psychosom 1990;54:172–179.

    Google Scholar 

  26. de Souza EB. Serotonin and dopamine receptors in the rat pituitary gland. Endocrinology 1986;119:1534–1542.

    Google Scholar 

  27. Rittenhouse PA, Bakkum EA, Levy AD, Li Q, Carnes M, Van den Kar LD. Evidence that ACTH secretion is regulated by serotonin receptors. J Pharmacol Exp Ther 1994; 271:1645–1655.

    Google Scholar 

  28. Fuller RW. Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats. Behav Brain Res 1996;73:215–219.

    Google Scholar 

  29. Dinan TG. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Life Sci 1996;58:1683–1694.

    Google Scholar 

  30. Calogero AE, Bagdy G, Szcmeredi K, Tartaglia ME, Gold PW, Chrousos GP. Mechanisms of serotonin receptoragonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. Endocrinology 1990;126:1888–1894.

    Google Scholar 

  31. Lefebvre H, Contesse V, Delarue C, Vaudry H, Kuhn JM. Serotonergic regulation of adrenocortical function. Horm Metab Res 1998;30:398–403.

    Google Scholar 

  32. Sonino N, Fava GA, Boscaro M. A role for life events in the pathogenesis of Cushing's disease. Clin Endocrinol 1993;38:261–264.

    Google Scholar 

  33. Sonino N, Fava GA. Psychosomatic aspects of Cushing's disease. Psychother Psychosom 1998;67:140–146.

    Google Scholar 

  34. Fiekers JF, Konopka LM. Serotonin-induced changes in membrane potential and cytosolic free calcium in a clonal pituitary cell life (AT-20) of cultured mouse corticotropes. Life Sci 1994;55:15–26.

    Google Scholar 

  35. Van Praag HM. Faulty cortisol/serotonin interplay. Psychiatry Res 1996;65:143–157.

    Google Scholar 

  36. Graeff FG, Guimares FS, De Andrade TGCS, Deakin JFW. Role of 5HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996;54:129–141.

    Google Scholar 

  37. Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol 1991;35:347–352.

    Google Scholar 

  38. Van Cauter E, Refetoff S. Evidence for two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion. N Engl J Med 1985;312:1343–1349.

    Google Scholar 

  39. Van Waveren Hogevorst CO, Koppeschaar HPF, Zelissen PMJ, Lips CJM, Garcia BM. Cortisol secretory patterns in Cushing's disease and response to cyproheptadine treatment. J Clin Endocrinol Metab 1996;81:652–655.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences, Division of Endocrinology, University of Padova, Padova, Italy

    Nicoletta Sonino, Francesco Fallo, Antonella Franceschetto, Piera Belluardo & Marco Boscaro

  2. Department of Psychiatry, State University of New York at Buffalo, Buffalo, New York, USA

    Giovanni A. Fava

Authors
  1. Nicoletta Sonino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni A. Fava
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Fallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonella Franceschetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Piera Belluardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marco Boscaro
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sonino, N., Fava, G.A., Fallo, F. et al. Effect of the Serotonin Antagonists Ritanserin and Ketanserin in Cushing's Disease. Pituitary 3, 55–59 (2000). https://doi.org/10.1023/A:1009986822146

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009986822146

Search

Navigation